4-(3-((5-(三氟甲基)吡啶-2-基)氧基)亚苄基)哌啶-1-甲酸叔丁酯 | 1020325-45-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(3-((5-(三氟甲基)吡啶-2-基)氧基)亚苄基)哌啶-1-甲酸叔丁酯
• 英文名称: tert-butyl 4-[3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene]piperidine-1-carboxylate
• 英文别名: 4-[3-(5-trifluoromethyl-pyridin-2-yloxy)-benzylidene]-piperidine-1-carboxylic acid tert-butyl ester；tert-Butyl 4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxylate；tert-butyl 4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxylate
• CAS: 1020325-45-4
• 化学式: C₂₃H₂₅F₃N₂O₃
• 分子量: 434.458
• InChiKey: QCDWBPDXKWWGSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(3-((5-(三氟甲基)吡啶-2-基)氧基)亚苄基)哌啶-1-甲酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 反应 17.33h， 以84%的产率得到2-(3-(piperidin-4-ylidenemethyl)phenoxy)-5-(trifluoromethyl)pyridine hydrochloride
  参考文献：
  名称：

  Biaryl Ether Urea Compounds

  摘要：

  本发明涉及式(I)的化合物或其药用可接受的盐；制备该化合物的方法；制备该化合物所用的中间体；含有该化合物的组合物；以及利用该化合物治疗与脂肪酸酰胺水解酶(FAAH)活性相关的疾病或症状。

  公开号：

  US20080261941A1
• 作为产物：
  描述：

  2-(3-(氯甲基)苯氧基)-5-(三氟甲基)吡啶 在 15-冠醚-5 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 22.58h， 生成 4-(3-((5-(三氟甲基)吡啶-2-基)氧基)亚苄基)哌啶-1-甲酸叔丁酯
  参考文献：
  名称：

  [EN] PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
  [FR] DÉRIVÉS D'URÉE DE PIPÉRIDINE UTILISÉS EN TANT QU'INHIBITEURS D'ÉPOXYDE HYDROLASE SOLUBLE

  摘要：

  Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of conditions and diseases mediated by soluble epoxide hydrolase.

  公开号：

  WO2022221493A1

文献信息

• Biaryl ether urea compounds
  申请人：Pfizer Inc.

  公开号：US08044052B2

  公开（公告）日：2011-10-25

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

  本发明涉及式（I）化合物或其药学上可接受的盐；制备该化合物的方法；制备该化合物的中间体；含有该化合物的组合物；以及使用该化合物治疗与脂肪酸酰胺水解酶（FAAH）活性相关的疾病或病况的用途。
• Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
  作者：Douglas S. Johnson、Cory Stiff、Scott E. Lazerwith、Suzanne R. Kesten、Lorraine K. Fay、Mark Morris、David Beidler、Marya B. Liimatta、Sarah E. Smith、David T. Dudley、Nalini Sadagopan、Shobha N. Bhattachar、Stephen J. Kesten、Tyzoon K. Nomanbhoy、Benjamin F. Cravatt、Kay Ahn

  DOI：10.1021/ml100190t

  日期：2011.2.10

  Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic and anti-inflammatory phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that. FAAH may represent an attractive therapeutic target for the treatment of inflammatory pain and other nervous system disorders. Herein, we report the discovery and characterization of a highly efficacious and selective FAAH inhibitor PR-04457845 (23). Compound 23 inhibits FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile of FAAH with high in vitro potency (k(inact)/K(i) and IC(50) values of 40300 M(-1) s(-1) and 7.2 nM, respectively, for human FAAH). Compound 23 has exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling. Oral administration of 23 at 0.1 mg/kg results in efficacy comparable to that of naproxen at 10 mg/kg in a rat model of inflammatory pain. Compound 23 is being evaluated in human clinical trials.
• Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: Identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds
  作者：Marvin J. Meyers、Scott A. Long、Matthew J. Pelc、Jane L. Wang、Scott J. Bowen、Mark C. Walker、Barbara A. Schweitzer、Heather M. Madsen、Ruth E. Tenbrink、Joseph McDonald、Sarah E. Smith、Susan Foltin、David Beidler、Atli Thorarensen

  DOI：10.1016/j.bmcl.2011.08.055

  日期：2011.11

  Herein we report the identification of two new fatty acid amide hydrolase (FAAH) inhibitor lead series with FAAH k(inact)/K(i) potency values greater than 1500 M (1) s (1). The two novel spirocyclic cores, 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane, clearly distinguished themselves from the other spirocyclic cores on the basis of their superior potency for FAAH. Lead compounds from these two series have suitable FAAH potency and selectivity for additional medicinal chemistry optimization. (C) 2011 Elsevier Ltd. All rights reserved.
• BIARYL ETHER UREA COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP2076508A2

  公开（公告）日：2009-07-08
• US8044052B2
  申请人：——

  公开号：US8044052B2

  公开（公告）日：2011-10-25